As part of its pursuit of scientific excellence, Merck continues to sign targeted, strategic collaborations with companies, institutions, academics and other organizations from around the world. Below are some examples of disclosed arrangements completed in 2004–2006.
- Partner/Licensor
- Location
- Target/Description
- Acumen
- United States
- Alzheimer’s Disease
- Advinus
- India
- Metabolic Disorders
- Agresearch
- New Zealand
- Animal Health
- Agensys
- Alnylam
- United States
- RNAi Technology
- Ambrilia
- Artemis
- Aveo
- Benitec
- Australia
- RNAi Technology
- Bioimage
- Denmark
- Screening Technology
- Bioxell
- Celera
- United States
- Alzheimer’s Disease
- Crucell
- CSL
- Foxhollow
- United States
- Cardiovascular
- Geron
- United States
- Oncology Vaccine
- Harvard University
- United States
- Ophthalmology
- Idera
- Ingenium
- Inovio
- United States
- Gene Delivery
- Intercell
- J. David Gladstone Institutes
- United States
- Alzheimer’s Disease
- Kinemed
- United States
- Metabolic Disorders
- Kyorin
- Lundbeck
- Melior Discovery
- Metabasis
- Metabasis
- Moffitt Cancer Center
- Mouse Clinical Institute
- Morphosys
- Neuromed
- Neuroptix
- United States
- Alzheimer’s Diagnostics
- Nicox
- Ono
- Parallele
- Paratek
- United States
- Antibiotics
- Perlegen
- Pierre Fabre
- PPD Development
- Prosidion
- PDL
- Rigel
- Robarts
- Sention
- United States
- Mental Retardation
- Shanghai Biochip
- Sigma-Aldrich
- Stratagene
- United States
- Gene Expression
- Sumitomo
- Sunesis
- Vertex
- XSIRA
- United States
- Screening Technology
- Znomics
|
